While such mutations are common in solid tumors, to date, regulatory approval of CDK4/6 inhibitors has only been granted for the treatment of hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER–) breast cancer [1,2,4]. Here, ERBB2 is linked to breast cancer.